Lv4
523 积分 2025-09-11 加入
[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
1天前
已完结
Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort
2天前
已完结
Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort
2天前
已关闭
Perioperative Apalutamide in High-Risk Localized Prostate Cancer
13天前
已完结
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
19天前
已完结
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience
19天前
已完结
Prognostic value of whole-body tumor SUV dispersion on baseline PSMA PET prior to PSMA radioligand therapy
21天前
已完结
Prognostic value of whole-body tumor SUV dispersion on baseline PSMA PET prior to PSMA radioligand therapy
21天前
已完结
SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis
21天前
已完结
Rechallenge and Extended [177Lu]Lu-PSMA Therapy in Metastatic Prostate Cancer
26天前
已完结
皖公网安备34019202002308
